MétaCan
Menu
Back to cohort
Record W4382344241 · doi:10.1093/brain/awad218

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

2023· article· en· W4382344241 on OpenAlexafffundabout
Sifat Sharmin, Izanne Roos, Steve Simpson, Charles B. Malpas, Marina Martínez-Sánchez, Serkan Özakbaş, Dana Horáková, Eva Havrdová, Francesco Patti, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Cavit Boz, Magd Zakaria, Marco Onofrj, Alessandra Lugaresi, Bianca Weinstock‐Guttman, Alexandre Prat, Marc Girard, Pierre Duquette, Murat Terzi, Maria Pia Amato, Rana Karabudak, François Grand’Maison, Samia J. Khoury, Pierre Grammond, Jeannette Lechner‐Scott, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Recai Türkoğlu, Ayşe Altıntaş, Davide Maimone, Allan G. Kermode, Nevin Shalaby, Vincent Van Pesch, Ernest Butler, Youssef Sidhom, Riadh Gouider, Saloua Mrabet, Oliver Gerlach, Aysun Soysal, Michael Barnett, Jens Kühle, Stella Hughes, J Maria, Suzanne Hodgkinson, Celia Oreja‐Guevara, Radek Ampapa, Thor Petersen, Cristina Ramo‐Tello, Daniele Spitaleri, Pamela McCombe, Bruce Taylor, Julie Prévost, Matteo Foschi, Mark Slee, Chris McGuigan, Guy Laureys, Liesbeth Van Hijfte, Koen de Gans, Claudio Solaro, Jiwon Oh, Richard Macdonell, Eduardo Agüera, Bhim Singhal, Orla Gray, Justin Garber, Bart Van Wijmeersch, Mihaela Simu, Tamara Castillo‐Triviño, José Luis Sánchez-Menoyo, Dheeraj Khurana, Abdullah Al‐Asmi, Talal Al‐Harbi, Norma Deri, Yára Dadalti Fragoso, Patrice H. Lalive, L. G. F. Sinnige, Cameron Shaw, Neil Shuey, Tünde Csépány, Ángel Pérez Sempere, Fraser Moore, D. Decoo, Barbara Willekens, Claudio Gobbi, Jennifer Massey, Todd A. Hardy, Tomáš Kalinčík

Bibliographic record

VenueBrain · 2023
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsCegep de Saint JeromeMcGill UniversityCentre intégré de santé et de services sociaux de Chaudière-AppalachesHôpital Charles-Le MoyneSt. Michael's HospitalUniversité de Montréal
FundersNational Health and Medical Research CouncilCanadian Institutes of Health ResearchSanofi GenzymeNovartis PharmaMultiple Sclerosis SocietyMultiple Sclerosis AustraliaGenentechF. Hoffmann-La RocheGrifolsUniversità di CataniaMultiple Sclerosis Society of CanadaBayer ScheringMylanMedical Research CouncilTeva Pharmaceutical IndustriesRoyal Melbourne Hospital Neuroscience FoundationUniversity of MelbourneNovartisFondazione Italiana Sclerosi MultiplaCelgeneBiogenAlexion PharmaceuticalsDementia AustraliaMerckSanofiEMD SeronoMonash UniversityRoche
KeywordsMultiple sclerosisMedicineProportional hazards modelCohortResidencePhysical therapyDemographyPediatricsInternal medicineImmunology

Abstract

fetched live from OpenAlex

Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors are regarded as drivers of this variation. No previous studies evaluated geographical variation in the risk of secondary progressive multiple sclerosis, an advanced form of multiple sclerosis that is characterized by steady accrual of irreversible disability. We evaluated differences in the risk of secondary progressive multiple sclerosis in relation to latitude and country of residence, modified by high-to-moderate efficacy immunotherapy in a geographically diverse cohort of patients with relapsing-remitting multiple sclerosis. The study included relapsing-remitting multiple sclerosis patients from the global MSBase registry with at least one recorded assessment of disability. Secondary progressive multiple sclerosis was identified as per clinician diagnosis. Sensitivity analyses used the operationalized definition of secondary progressive multiple sclerosis and the Swedish decision tree algorithm. A proportional hazards model was used to estimate the cumulative risk of secondary progressive multiple sclerosis by country of residence (latitude), adjusted for sex, age at disease onset, time from onset to relapsing-remitting phase, disability (Multiple Sclerosis Severity Score) and relapse activity at study inclusion, national multiple sclerosis prevalence, government health expenditure, and proportion of time treated with high-to-moderate efficacy disease-modifying therapy. Geographical variation in time from relapsing-remitting phase to secondary progressive phase of multiple sclerosis was modelled through a proportional hazards model with spatially correlated frailties. We included 51 126 patients (72% female) from 27 countries. The median survival time from relapsing-remitting phase to secondary progressive multiple sclerosis among all patients was 39 (95% confidence interval: 37 to 43) years. Higher latitude [median hazard ratio = 1.21, 95% credible interval (1.16, 1.26)], higher national multiple sclerosis prevalence [1.07 (1.03, 1.11)], male sex [1.30 (1.22, 1.39)], older age at onset [1.35 (1.30, 1.39)], higher disability [2.40 (2.34, 2.47)] and frequent relapses [1.18 (1.15, 1.21)] at inclusion were associated with increased hazard of secondary progressive multiple sclerosis. Higher proportion of time on high-to-moderate efficacy therapy substantially reduced the hazard of secondary progressive multiple sclerosis [0.76 (0.73, 0.79)] and reduced the effect of latitude [interaction: 0.95 (0.92, 0.99)]. At the country-level, patients in Oman, Tunisia, Iran and Canada had higher risks of secondary progressive multiple sclerosis relative to the other studied regions. Higher latitude of residence is associated with a higher probability of developing secondary progressive multiple sclerosis. High-to-moderate efficacy immunotherapy can mitigate some of this geographically co-determined risk.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.005
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.633
Threshold uncertainty score0.560

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.053
GPT teacher head0.300
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations26
Published2023
Admission routes3
Has abstractyes

Explore more

Same venueBrainSame topicMultiple Sclerosis Research StudiesFrench-language works237,207